tPA is a clot-buster used to treat stroke, but if it's given too late after stroke onset, it can cause complications like hemorrhage. Daniel Lawrence and his colleagues show that a US Food and Drug Administration–approved kinase inhibitor, Gleevec, can prevent this side effect, thereby extending tPA's therapeutic window.
- Enming J Su
- Linda Fredriksson
- Daniel A Lawrence
